Literature DB >> 8993510

Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.

M C Bissery1, P Vrignaud, F Lavelle, G G Chabot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8993510     DOI： 10.1111/j.1749-6632.1996.tb26386.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  6 in total

1.  A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.

Authors:  Gwi-Moon Seo; Raja Shekar Rachakatla; Sivasai Balivada; Marla Pyle; Tej B Shrestha; Matthew T Basel; Carl Myers; Hongwang Wang; Masaaki Tamura; Stefan H Bossmann; Deryl L Troyer
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

Review 2.  Array of translational systems pharmacodynamic models of anti-cancer drugs.

Authors:  Sihem Ait-Oudhia; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-10-22       Impact factor: 2.745

Review 3.  Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer.

Authors:  Monika Wierdl; Lyudmila Tsurkan; M Jason Hatfield; Philip M Potter
Journal:  Br J Pharmacol       Date:  2016-08-22       Impact factor: 8.739

4.  Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-02       Impact factor: 4.130

Review 5.  Interaction of carbamazepine with herbs, dietary supplements, and food: a systematic review.

Authors:  Sophia Yui Kau Fong; Qiong Gao; Zhong Zuo
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-19       Impact factor: 2.629

6.  UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

Authors:  E Marcuello; A Altés; A Menoyo; E Del Rio; M Gómez-Pardo; M Baiget
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.